32
https://pubmed.ncbi.nlm.nih.gov/38116014
Inhibiting focal adhesion kinase 2 with Defactinib reduces heterotopic ossification and inflammation in a blast-related extremity injury model.
https://pubmed.ncbi.nlm.nih.gov/38116014
Inhibiting focal adhesion kinase 2 with Defactinib reduces heterotopic ossification and inflammation in a blast-related extremity injury model.